Is pharma running out of brainy ideas?

By G. Miller. 2010

261 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

A Role for Fragment-Based Drug Design in Developing Novel Lead Compounds for Central Nervous System Targets (2015, background): “…SERT, serotonin transporter protein; VHTS, virtual high-throughput screening; VS, virtual screening. companies to drastically limit research expenses, and while outsourcing is an option carrying benefits and liabilities (3), development of new, more cost-effective drug design methods is a priority.”
Using Neuroscience to Help Understand Fear and Anxiety: A Two-System Framework. (2016, background): “The pharmaceutical industry has concluded that the probability of discovering new treatments is low (2, 110), and it has curtailed investment in future psychotropic medication discovery.”
Serotonin and brain function: a tale of two receptors (2017, background): “For the brave new psychiatry of the future – that many would like to see (Miller, 2010) – decisions about whether to passively endure or actively address, may become increasingly pertinent.”